Clinical trial · Interventional
Radiofrequency Ablation During Surgery in Treating Patients With Non-Small Cell Lung Cancer
Pilot Study: Radiofrequency Ablation Of Resectable Non-Small Cell Lung Cancer
NCT00039507CI-TRIAL-00003143completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. Combining radiofrequency ablation with surgery may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining radiofrequency ablation with surgery in treating patients who have stage I or stage II non-small cell lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional surgery | Procedure | — | UNRESOLVED |
| radiofrequency ablation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of malignant non-small cell lung cancer (NSCLC) * Intraoperative needle biopsy confirmation allowed * Resectable disease (stage I or II) * All tissue to be treated by radiofrequency tumor ablation must be completely contained within boundaries of planned lung resection * Medically fit to undergo lung resection PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior or concurrent biologic therapy Chemotherapy: * No prior or concurrent chemotherapy Endocrine therapy: * No prior or concurrent endocrine therapy Radiotherapy: * No prior or concurrent radiotherapy Surgery: * See Disease Characteristics Other: * No other prior therapy for NSCLC
References
Publications (0)
Data not yet available
No reference posted for this study.